JP Morgan Chase’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-7,821
| Closed | -$411K | – | 6156 |
|
|
2020
Q3 | $411K | Sell |
7,821
-1,788
| -19% | -$110K | ﹤0.01% | 4066 |
|
|
2020
Q2 | $589K | Sell |
9,609
-619
| -6% | -$35.8K | ﹤0.01% | 3785 |
|
|
2020
Q1 | $579K | Sell |
10,228
-326
| -3% | -$18.6K | ﹤0.01% | 3748 |
|
|
2019
Q4 | $601K | Sell |
10,554
-9,317
| -47% | -$494K | ﹤0.01% | 4148 |
|
|
2019
Q3 | $1.06M | Buy |
19,871
+8,188
| +70% | +$477K | ﹤0.01% | 3802 |
|
|
2019
Q2 | $701K | Buy |
11,683
+1,220
| +12% | +$76.8K | ﹤0.01% | 4056 |
|
|
2019
Q1 | $653K | Buy |
10,463
+6,152
| +143% | +$407K | ﹤0.01% | 4055 |
|
|
2018
Q4 | $261K | Buy |
4,311
+2,978
| +223% | +$178K | ﹤0.01% | 4466 |
|
|
2018
Q3 | $78K | Buy |
1,333
+435
| +48% | +$22.2K | ﹤0.01% | 5039 |
|
|
2018
Q2 | $40K | Sell |
898
-240
| -21% | -$10.3K | ﹤0.01% | 5155 |
|
|
2018
Q1 | $50K | Sell |
1,138
-81
| -7% | -$3.4K | ﹤0.01% | 4814 |
|
|
2017
Q4 | $53K | Buy |
+1,219
| New | +$54.8K | ﹤0.01% | 4880 |
|
|
2016
Q3 | – | Sell |
-966
| Closed | -$39K | – | 4941 |
|
|
2016
Q2 | $39K | Buy |
966
+853
| +755% | +$31.2K | ﹤0.01% | 4111 |
|
|
2016
Q1 | $4K | Buy |
113
+39
| +53% | +$1.43K | ﹤0.01% | 4424 |
|
|
2015
Q4 | $3K | Buy |
+74
| New | +$3.71K | ﹤0.01% | 4474 |
|
Other funds holding BSTC
JP Morgan Chase's BSTC Position: Q4 2020 in Review
JP Morgan Chase sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 7,821 shares — an estimated $411K sold.
JP Morgan Chase first reported a position in BSTC in Q4 2015 and held it in 15 quarters. The position peaked at $1.06M in Q3 2019. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- JP Morgan Chase reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- JP Morgan Chase sold 7,821 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $411K.
- JP Morgan Chase first reported a position in BioSpecifics Technologies Corp. in Q4 2015 and held it in 15 quarters.
- JP Morgan Chase's BioSpecifics Technologies Corp. position peaked at $1.06M in Q3 2019.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.